| Dr Fawad H Rizvi, DO | |
|
11650 Belleville Rd, Suite 105, Belleville, MI 48111 | |
| (734) 325-6282 | |
| (734) 865-1234 |
| Full Name | Dr Fawad H Rizvi |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 19 Years |
| Location | 11650 Belleville Rd, Belleville, Michigan |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1700107349 | NPI | - | NPPES |
| 5101016547 | Other | MI | STATE LICENSE # |
| 12149649 | Other | MI | CAQH |
| MI3786-001 | Other | MI | MEDICARE IND PIN # |
| 1700107349 | Other | MI | BCBS TYPE 1 (IND) NPI # |
| 5315047618 | Other | MI | CDS # |
| 5820929 | Other | MI | BCBS TYPE 1 PIN # IND |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208VP0014X | Pain Medicine - Interventional Pain Medicine | 5101016547 (Michigan) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Beaumont Hospital - Wayne | Wayne, MI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Comprehensive Pain Solutions Pllc | 0547440745 | 6 |
News Archive
The American Heart Association and the American College of Cardiology have released their latest 121 page guidelines on risk assessment and management of high cholesterol for people who are at a greater risk of heart attacks or strokes.
New research from UBC shows that when humans speed up the usually slow process of evolution by introducing new species, it can result in a lasting impact on the ecosystem. The phenomenon is known as reverse speciation and researchers witnessed it in Enos Lake on Vancouver Island where two similar species of threespine stickleback fish disappeared within three years.
Dyadic International, Inc. today announced financial results for the third quarter ended September 30, 2009. The financial information contained in this press release should be read in conjunction with the financial statements and footnotes for the three and nine month periods ended September 30, 2009 as well as the financial statements, footnotes and independent auditors' report for the year ended December 31, 2008 which have been posted on the Pink Sheets website at www.pinksheets.com and on Dyadic's website at www.dyadic.com.
Protalix BioTherapeutics, Inc., announced today it has submitted validation data regarding the Company's manufacturing process for taliglucerase alfa to the U.S. Food and Drug Administration (FDA). The Company made the submission in response to a request from the FDA for validation data from the Company's upgraded manufacturing facility. The FDA is currently reviewing the Company's New Drug Application (NDA) for taliglucerase alfa for the treatment of Gaucher disease.
While rhinoplasty surgery is one of the most common surgery performed worldwide, many associate a stigma with it due to the unflattering nose surgeries of high profile celebrities.
› Verified 5 days ago
| Entity Name | Comprehensive Pain Solutions Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437478716 PECOS PAC ID: 0547440745 Enrollment ID: O20110204000542 |
News Archive
The American Heart Association and the American College of Cardiology have released their latest 121 page guidelines on risk assessment and management of high cholesterol for people who are at a greater risk of heart attacks or strokes.
New research from UBC shows that when humans speed up the usually slow process of evolution by introducing new species, it can result in a lasting impact on the ecosystem. The phenomenon is known as reverse speciation and researchers witnessed it in Enos Lake on Vancouver Island where two similar species of threespine stickleback fish disappeared within three years.
Dyadic International, Inc. today announced financial results for the third quarter ended September 30, 2009. The financial information contained in this press release should be read in conjunction with the financial statements and footnotes for the three and nine month periods ended September 30, 2009 as well as the financial statements, footnotes and independent auditors' report for the year ended December 31, 2008 which have been posted on the Pink Sheets website at www.pinksheets.com and on Dyadic's website at www.dyadic.com.
Protalix BioTherapeutics, Inc., announced today it has submitted validation data regarding the Company's manufacturing process for taliglucerase alfa to the U.S. Food and Drug Administration (FDA). The Company made the submission in response to a request from the FDA for validation data from the Company's upgraded manufacturing facility. The FDA is currently reviewing the Company's New Drug Application (NDA) for taliglucerase alfa for the treatment of Gaucher disease.
While rhinoplasty surgery is one of the most common surgery performed worldwide, many associate a stigma with it due to the unflattering nose surgeries of high profile celebrities.
› Verified 5 days ago
| Entity Name | Detroit Anesthesia Group Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1316212988 PECOS PAC ID: 3173789088 Enrollment ID: O20120723000043 |
News Archive
The American Heart Association and the American College of Cardiology have released their latest 121 page guidelines on risk assessment and management of high cholesterol for people who are at a greater risk of heart attacks or strokes.
New research from UBC shows that when humans speed up the usually slow process of evolution by introducing new species, it can result in a lasting impact on the ecosystem. The phenomenon is known as reverse speciation and researchers witnessed it in Enos Lake on Vancouver Island where two similar species of threespine stickleback fish disappeared within three years.
Dyadic International, Inc. today announced financial results for the third quarter ended September 30, 2009. The financial information contained in this press release should be read in conjunction with the financial statements and footnotes for the three and nine month periods ended September 30, 2009 as well as the financial statements, footnotes and independent auditors' report for the year ended December 31, 2008 which have been posted on the Pink Sheets website at www.pinksheets.com and on Dyadic's website at www.dyadic.com.
Protalix BioTherapeutics, Inc., announced today it has submitted validation data regarding the Company's manufacturing process for taliglucerase alfa to the U.S. Food and Drug Administration (FDA). The Company made the submission in response to a request from the FDA for validation data from the Company's upgraded manufacturing facility. The FDA is currently reviewing the Company's New Drug Application (NDA) for taliglucerase alfa for the treatment of Gaucher disease.
While rhinoplasty surgery is one of the most common surgery performed worldwide, many associate a stigma with it due to the unflattering nose surgeries of high profile celebrities.
› Verified 5 days ago
| Entity Name | United Pain Therapies Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427483403 PECOS PAC ID: 0446487029 Enrollment ID: O20131206000847 |
News Archive
The American Heart Association and the American College of Cardiology have released their latest 121 page guidelines on risk assessment and management of high cholesterol for people who are at a greater risk of heart attacks or strokes.
New research from UBC shows that when humans speed up the usually slow process of evolution by introducing new species, it can result in a lasting impact on the ecosystem. The phenomenon is known as reverse speciation and researchers witnessed it in Enos Lake on Vancouver Island where two similar species of threespine stickleback fish disappeared within three years.
Dyadic International, Inc. today announced financial results for the third quarter ended September 30, 2009. The financial information contained in this press release should be read in conjunction with the financial statements and footnotes for the three and nine month periods ended September 30, 2009 as well as the financial statements, footnotes and independent auditors' report for the year ended December 31, 2008 which have been posted on the Pink Sheets website at www.pinksheets.com and on Dyadic's website at www.dyadic.com.
Protalix BioTherapeutics, Inc., announced today it has submitted validation data regarding the Company's manufacturing process for taliglucerase alfa to the U.S. Food and Drug Administration (FDA). The Company made the submission in response to a request from the FDA for validation data from the Company's upgraded manufacturing facility. The FDA is currently reviewing the Company's New Drug Application (NDA) for taliglucerase alfa for the treatment of Gaucher disease.
While rhinoplasty surgery is one of the most common surgery performed worldwide, many associate a stigma with it due to the unflattering nose surgeries of high profile celebrities.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Fawad H Rizvi, DO Po Box 1706, Belleville, MI 48112-1706 Ph: (734) 325-6282 | Dr Fawad H Rizvi, DO 11650 Belleville Rd, Suite 105, Belleville, MI 48111 Ph: (734) 325-6282 |
News Archive
The American Heart Association and the American College of Cardiology have released their latest 121 page guidelines on risk assessment and management of high cholesterol for people who are at a greater risk of heart attacks or strokes.
New research from UBC shows that when humans speed up the usually slow process of evolution by introducing new species, it can result in a lasting impact on the ecosystem. The phenomenon is known as reverse speciation and researchers witnessed it in Enos Lake on Vancouver Island where two similar species of threespine stickleback fish disappeared within three years.
Dyadic International, Inc. today announced financial results for the third quarter ended September 30, 2009. The financial information contained in this press release should be read in conjunction with the financial statements and footnotes for the three and nine month periods ended September 30, 2009 as well as the financial statements, footnotes and independent auditors' report for the year ended December 31, 2008 which have been posted on the Pink Sheets website at www.pinksheets.com and on Dyadic's website at www.dyadic.com.
Protalix BioTherapeutics, Inc., announced today it has submitted validation data regarding the Company's manufacturing process for taliglucerase alfa to the U.S. Food and Drug Administration (FDA). The Company made the submission in response to a request from the FDA for validation data from the Company's upgraded manufacturing facility. The FDA is currently reviewing the Company's New Drug Application (NDA) for taliglucerase alfa for the treatment of Gaucher disease.
While rhinoplasty surgery is one of the most common surgery performed worldwide, many associate a stigma with it due to the unflattering nose surgeries of high profile celebrities.
› Verified 5 days ago